Tissue and cell type-associated traits map for all cell types in [AdultUreter] . Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-05 as default, and users can change it to 1e-04, 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple trait-associated-gene (TAG) sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below. Users could further select to only show the association for those ‘tissue-specfic cell types’ defined from ontology analysis.
Table. List of Tissue-cell type associated traits pairs for [AdultUreter]. If the network above is too complicated, the users could obtain the association information from the table at bottom. Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
| Cell type | Trait name | Trait full name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
|---|---|---|---|---|---|---|---|---|---|
| B cell (Plasmocyte) | Age At Menarche | Age At Menarche | ETC | Perry | 2014 | NA | 182413 | 1.00e-2 | 3.95e-2 |
| B cell (Plasmocyte) | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-3 | 6.80e-3 |
| B cell (Plasmocyte) | Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | MTC | van-Rheenen | 2016 | 12577 | 23475 | 1.00e-2 | 2.22e-2 |
| B cell (Plasmocyte) | Anorexia Nervosa | Anorexia Nervosa | MTC | Duncan | 2017 | 3495 | 10982 | 5.00e-2 | 4.06e-2 |
| Epithelial cell (intermediated) | Breast Cancer | Breast Cancer | MTC | Hunter | 2007 | NA | 1145 | 5.00e-2 | 4.03e-2 |
| B cell (Plasmocyte) | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-4 | 3.81e-2 |
| B cell (Plasmocyte) | Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-3 | 2.10e-2 |
| B cell (Plasmocyte) | MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-3 | 4.38e-2 |
| B cell (Plasmocyte) | Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 1.00e-5 | 3.71e-2 |
| B cell (Plasmocyte) | Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-2 | 2.01e-2 |
| Epithelial cell (intermediated) | Obsessive Compulsive Disorder | Obsessive Compulsive Disorder | ETC | Arnold | 2017 | 2688 | 7037 | 1.00e-2 | 2.69e-2 |
| B cell (Plasmocyte) | Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-2 | 2.98e-2 |
| B cell (Plasmocyte) | Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-3 | 6.74e-3 |
| B cell (Plasmocyte) | Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-4 | 4.91e-3 |
| B cell (Plasmocyte) | Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-5 | 1.72e-3 |
| Epithelial cell (intermediated) | Sleep Duration BMI Adjusted | Sleep Duration BMI Adjusted | MTC | Marinelli | 2016 | NA | 10554 | 5.00e-2 | 6.93e-3 |
| Epithelial cell (intermediated) | Sleep Duration BMI Adjusted | Sleep Duration BMI Adjusted | MTC | Marinelli | 2016 | NA | 10554 | 1.00e-2 | 3.65e-2 |
| Epithelial cell (intermediated) | Sleep Duration | Sleep Duration | MTC | Marinelli | 2016 | NA | 10554 | 5.00e-2 | 1.81e-2 |
| Epithelial cell (intermediated) | Sleep Duration | Sleep Duration | MTC | Marinelli | 2016 | NA | 10554 | 1.00e-2 | 7.62e-3 |
| B cell (Plasmocyte) | Type 2 Diabetes | Type 2 Diabetes | MTC | Wood | 2016 | 4040 | 113735 | 5.00e-2 | 2.27e-2 |
| B cell (Plasmocyte) | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 5.00e-2 | 4.07e-2 |
| Epithelial cell (intermediated) | Warfarin maintenance dose | Warfarin maintenance dose | MTC | Cooper | 2008 | NA | 181 | 1.00e-2 | 3.71e-2 |
| Epithelial cell (intermediated) | Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 5.00e-2 | 1.40e-2 |
| Epithelial cell (intermediated) | Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 1.00e-2 | 1.28e-2 |
| Epithelial cell (intermediated) | Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 5.00e-2 | 4.93e-2 |
| Epithelial cell (intermediated) | Anthropometric Extremes | Obesity Class 3 | MTC | Berndt | 2013 | 2896 | 65840 | 5.00e-2 | 2.36e-2 |
| Epithelial cell (intermediated) | Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 5.00e-2 | 3.91e-3 |
| Epithelial cell (intermediated) | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 3.85e-2 |
| Epithelial cell (intermediated) | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 5.00e-2 | 4.45e-2 |
| B cell (Plasmocyte) | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 5.00e-2 | 5.36e-3 |
| B cell (Plasmocyte) | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-2 | 9.36e-3 |
| B cell (Plasmocyte) | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-3 | 1.23e-2 |
| B cell (Plasmocyte) | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 5.00e-2 | 2.66e-3 |
| B cell (Plasmocyte) | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-2 | 2.02e-2 |
| B cell (Plasmocyte) | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-4 | 3.46e-2 |
| B cell (Plasmocyte) | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-2 | 3.07e-2 |
| B cell (Plasmocyte) | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-3 | 4.73e-2 |
| B cell (Plasmocyte) | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-4 | 1.39e-2 |
| B cell (Plasmocyte) | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-5 | 3.87e-3 |
| B cell (Plasmocyte) | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 1.27e-2 |
| B cell (Plasmocyte) | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 1.94e-2 |
| B cell (Plasmocyte) | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 1.24e-2 |
| B cell (Plasmocyte) | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 4.82e-4 |
| B cell (Plasmocyte) | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 3.31e-4 |
| B cell (Plasmocyte) | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 3.91e-2 |
| B cell (Plasmocyte) | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 2.87e-2 |
| B cell (Plasmocyte) | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 1.77e-2 |
| Epithelial cell (intermediated) | BMI Physical Activity Interaction | BMI Inactive European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 2.63e-2 |
| B cell (Plasmocyte) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 9.89e-3 |
| B cell (Plasmocyte) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.51e-2 |
| B cell (Plasmocyte) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 2.54e-2 |
| B cell (Plasmocyte) | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.98e-2 |
| B cell (Plasmocyte) | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 1.62e-2 |
| B cell (Plasmocyte) | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 2.55e-2 |
| Epithelial cell (intermediated) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.70e-2 |
| B cell (Plasmocyte) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.98e-2 |
| B cell (Plasmocyte) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 3.41e-3 |
| B cell (Plasmocyte) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 8.28e-3 |
| B cell (Plasmocyte) | Bone Mineral Density | Femoral Neck Bone Mineral Density Men | MTC | Estrada | 2012 | NA | 32961 | 5.00e-2 | 3.89e-2 |
| B cell (Plasmocyte) | Bone Mineral Density | Lumbar Spine Bone Mineral Density Men | MTC | Estrada | 2012 | NA | 31800 | 5.00e-2 | 4.53e-2 |
| B cell (Plasmocyte) | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 30 to 45 | MTC | Medina-Gomez | 2018 | NA | 10062 | 5.00e-2 | 3.85e-2 |
| B cell (Plasmocyte) | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 1.00e-2 | 2.41e-2 |
| B cell (Plasmocyte) | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 5.00e-2 | 2.92e-2 |
| B cell (Plasmocyte) | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density Under 15 | MTC | Medina-Gomez | 2018 | NA | 11807 | 1.00e-3 | 1.15e-2 |
| Epithelial cell (intermediated) | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-5 | 4.52e-2 |
| B cell (Plasmocyte) | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-3 | 2.95e-2 |
| Epithelial cell (intermediated) | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-2 | 3.93e-2 |
| B cell (Plasmocyte) | Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Women | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 2.25e-2 |
| B cell (Plasmocyte) | Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 2.02e-2 |
| B cell (Plasmocyte) | Facial Shape | Mod1 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.30e-2 |
| Epithelial cell (intermediated) | Facial Shape | Mod10 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.33e-2 |
| B cell (Plasmocyte) | Facial Shape | Mod10 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.33e-2 |
| Epithelial cell (intermediated) | Facial Shape | Mod15 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.27e-2 |
| Epithelial cell (intermediated) | Facial Shape | Mod23 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.92e-3 |
| Epithelial cell (intermediated) | Facial Shape | Mod31 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.38e-2 |
| Epithelial cell (intermediated) | Facial Shape | Mod34 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.61e-2 |
| Epithelial cell (intermediated) | Facial Shape | Mod34 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.62e-3 |
| Epithelial cell (intermediated) | Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 5.63e-3 |
| Epithelial cell (intermediated) | Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 8.44e-3 |
| B cell (Plasmocyte) | Facial Shape | Mod43 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.24e-2 |
| B cell (Plasmocyte) | Facial Shape | Mod44 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.61e-2 |
| Epithelial cell (intermediated) | Facial Shape | Mod44 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.83e-2 |
| Epithelial cell (intermediated) | Facial Shape | Mod46 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.93e-3 |
| B cell (Plasmocyte) | Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 5.00e-2 | 3.48e-2 |
| Epithelial cell (intermediated) | Gestational Weight Gain | Late Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 8641 | 5.00e-2 | 1.99e-3 |
| Epithelial cell (intermediated) | Glucose Stimulated Insulin Secretion | AUC Insulin Over AUC Glucose | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 3.62e-2 |
| B cell (Plasmocyte) | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.98e-2 |
| B cell (Plasmocyte) | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 4.86e-2 |
| B cell (Plasmocyte) | Glycemic Traits BMI Corrected | Fasting Glucose | MTC | Manning | 2012 | NA | 58074 | 1.00e-2 | 1.75e-3 |
| Epithelial cell (intermediated) | Glycemic Traits BMI Corrected | Fasting Glucose Interaction With BMI | MTC | Manning | 2012 | NA | 58074 | 5.00e-2 | 4.28e-3 |
| B cell (Plasmocyte) | Glycemic Traits | Fasting Glucose | ETC | Dupuis | 2010 | NA | 46186 | 1.00e-3 | 1.15e-2 |
| Epithelial cell (intermediated) | Glycemic Traits | HOMA IR | MTC | Dupuis | 2010 | NA | 37037 | 5.00e-2 | 2.63e-2 |
| B cell (Plasmocyte) | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 5.00e-2 | 8.78e-3 |
| B cell (Plasmocyte) | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-2 | 4.85e-3 |
| B cell (Plasmocyte) | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 2.36e-2 |
| B cell (Plasmocyte) | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-4 | 2.78e-2 |
| B cell (Plasmocyte) | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-5 | 1.58e-2 |
| B cell (Plasmocyte) | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-5 | 2.48e-2 |
| Epithelial cell (intermediated) | Insulin Secretion | Acute Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2087 | 5.00e-2 | 4.07e-2 |
| Epithelial cell (intermediated) | Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 2.10e-2 |
| Epithelial cell (intermediated) | Ischaemic Stroke | Large Vessel Disease | MTC | Traylor | 2012 | 1877 | 12285 | 5.00e-2 | 4.64e-3 |
| Epithelial cell (intermediated) | Lymphocyte Subsets | CD56 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.23e-2 |
| B cell (Plasmocyte) | TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 4.87e-3 |
| B cell (Plasmocyte) | TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-2 | 4.19e-3 |
| Epithelial cell (intermediated) | TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 2.66e-2 |
| Epithelial cell (intermediated) | Reproductive Behavior | Age First Birth Pooled | ETC | Barban | 2016 | NA | 238064 | 1.00e-3 | 3.65e-2 |
| B cell (Plasmocyte) | Reproductive Behavior | Number Children Even Born Pooled | MTC | Barban | 2016 | NA | 329139 | 5.00e-2 | 3.24e-2 |
| B cell (Plasmocyte) | Reproductive Behavior | Number Children Ever Born Female | MTC | Barban | 2016 | NA | 225230 | 5.00e-2 | 4.20e-2 |
| B cell (Plasmocyte) | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 4.03e-2 |
| B cell (Plasmocyte) | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 5.84e-3 |
| B cell (Plasmocyte) | Statin Efficacy | Delta TC With Statin | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 1.45e-2 |
| B cell (Plasmocyte) | Statin Efficacy | Delta TG | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 2.95e-2 |
| B cell (Plasmocyte) | Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 1.77e-2 |
| B cell (Plasmocyte) | Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 1.02e-2 |
| Epithelial cell (intermediated) | Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-2 | 1.73e-2 |
| Epithelial cell (intermediated) | Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-3 | 2.03e-2 |
| B cell (Plasmocyte) | Waist Format 1 | Hip Circumference Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 4.54e-2 |
| B cell (Plasmocyte) | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 2.31e-2 |
| B cell (Plasmocyte) | Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 3.83e-2 |
| B cell (Plasmocyte) | SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-4 | 2.70e-2 |
| B cell (Plasmocyte) | SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-5 | 2.54e-2 |
| Epithelial cell (intermediated) | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 1.57e-2 |
| B cell (Plasmocyte) | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 4.03e-2 |
| B cell (Plasmocyte) | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 4.26e-2 |
| Epithelial cell (intermediated) | PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 5.00e-2 | 2.66e-2 |
| Epithelial cell (intermediated) | PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 1.00e-2 | 2.89e-2 |
| B cell (Plasmocyte) | HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 2.55e-2 |
| B cell (Plasmocyte) | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 1.37e-2 |
| B cell (Plasmocyte) | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 3.73e-2 |
| Epithelial cell (intermediated) | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 3.03e-2 |
| B cell (Plasmocyte) | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-2 | 2.83e-2 |
| B cell (Plasmocyte) | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 5.00e-2 | 3.43e-2 |
| B cell (Plasmocyte) | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-2 | 8.54e-3 |
| B cell (Plasmocyte) | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-3 | 6.36e-3 |
| B cell (Plasmocyte) | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 1.81e-2 |
| B cell (Plasmocyte) | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 2.85e-2 |
| B cell (Plasmocyte) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 5.00e-2 | 7.66e-3 |
| B cell (Plasmocyte) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-2 | 2.47e-3 |
| B cell (Plasmocyte) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 2.26e-3 |
| B cell (Plasmocyte) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 1.26e-2 |
| B cell (Plasmocyte) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 1.40e-2 |
| B cell (Plasmocyte) | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 5.00e-2 | 2.00e-2 |
| B cell (Plasmocyte) | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-2 | 7.95e-3 |
| Epithelial cell (intermediated) | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 5.00e-2 | 1.60e-2 |
| B cell (Plasmocyte) | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 4.84e-2 |
| B cell (Plasmocyte) | Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 1.12e-2 |
| B cell (Plasmocyte) | Neuroticism | General factor of neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-2 | 5.03e-3 |
| B cell (Plasmocyte) | Neuroticism | Worry-vulnerability-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-5 | 3.54e-2 |
| B cell (Plasmocyte) | Neuroticism | Anxiety-tension-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-5 | 3.54e-2 |
| B cell (Plasmocyte) | Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 5.00e-2 | 4.40e-3 |
| B cell (Plasmocyte) | Glycine level | Glycine level | ETC | Wittemans | 2019 | NA | 80003 | 5.00e-2 | 1.76e-2 |
| B cell (Plasmocyte) | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 5.00e-2 | 3.04e-2 |
| B cell (Plasmocyte) | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-4 | 3.92e-2 |
| B cell (Plasmocyte) | Morning person | Morning person | ETC | Jones | 2019 | 252287 | 150908 | 1.00e-2 | 1.97e-2 |
| Epithelial cell (intermediated) | Obesity | Obese children vs thin adults | ETC | McKay | 2019 | 1471 | 1456 | 5.00e-2 | 3.35e-2 |
| Epithelial cell (intermediated) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 8.63e-3 |
| Epithelial cell (intermediated) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 1.55e-2 |
| B cell (Plasmocyte) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 4.29e-2 |
| B cell (Plasmocyte) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 1.55e-2 |
| B cell (Plasmocyte) | Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 4.29e-2 |
| B cell (Plasmocyte) | Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-4 | 7.25e-3 |
| B cell (Plasmocyte) | Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 5.00e-2 | 1.85e-2 |
| B cell (Plasmocyte) | Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 1.00e-4 | 4.22e-2 |
| B cell (Plasmocyte) | Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 5.00e-2 | 1.49e-2 |
| B cell (Plasmocyte) | Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 1.00e-2 | 2.12e-2 |
| B cell (Plasmocyte) | Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 5.00e-2 | 2.44e-2 |
| B cell (Plasmocyte) | Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-3 | 4.03e-2 |
| B cell (Plasmocyte) | Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-2 | 1.74e-2 |
| B cell (Plasmocyte) | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-5 | 2.20e-2 |
| B cell (Plasmocyte) | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-4 | 4.25e-2 |
| B cell (Plasmocyte) | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-5 | 4.61e-3 |
| Epithelial cell (intermediated) | Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 5.00e-2 | 4.31e-2 |
| B cell (Plasmocyte) | Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 5.00e-2 | 1.83e-2 |
| B cell (Plasmocyte) | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-2 | 2.11e-2 |
| B cell (Plasmocyte) | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-3 | 2.05e-2 |
| B cell (Plasmocyte) | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-4 | 1.14e-2 |
| B cell (Plasmocyte) | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 2.57e-2 |
| B cell (Plasmocyte) | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 4.32e-2 |
| Epithelial cell (intermediated) | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 5.00e-2 | 9.32e-3 |
| B cell (Plasmocyte) | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-3 | 3.48e-2 |
| B cell (Plasmocyte) | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-5 | 1.62e-2 |
| B cell (Plasmocyte) | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 2.21e-3 |
| B cell (Plasmocyte) | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 3.65e-2 |
| Epithelial cell (intermediated) | Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 1.03e-2 |
| B cell (Plasmocyte) | Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-4 | 2.55e-2 |
| Epithelial cell (intermediated) | Renal cell carcinoma | Renal cell carcinoma female | ETC | Laskar RS | 2019 | 1,992 | 3,095 | 5.00e-2 | 4.93e-2 |
| B cell (Plasmocyte) | Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 1.70e-2 |
| B cell (Plasmocyte) | Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 5.00e-2 | 1.55e-2 |
| B cell (Plasmocyte) | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-3 | 4.41e-2 |
| B cell (Plasmocyte) | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-5 | 8.29e-3 |
| Epithelial cell (intermediated) | same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-2 | 3.48e-2 |
| Epithelial cell (intermediated) | same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 1.00e-2 | 3.73e-2 |
| B cell (Plasmocyte) | Occipital lobe volume | Occipital lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 3.76e-3 |
| Epithelial cell (intermediated) | Parietal lobe volume | Parietal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 2.65e-2 |
| Epithelial cell (intermediated) | Parietal lobe volume | Parietal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-2 | 6.07e-3 |
| B cell (Plasmocyte) | Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-2 | 3.60e-2 |
| B cell (Plasmocyte) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 5.00e-2 | 4.22e-2 |
| B cell (Plasmocyte) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-2 | 3.96e-3 |
| B cell (Plasmocyte) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-3 | 2.45e-2 |
| B cell (Plasmocyte) | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-4 | 2.95e-2 |
| Epithelial cell (intermediated) | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-2 | 3.51e-2 |
| B cell (Plasmocyte) | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-3 | 2.06e-2 |
| B cell (Plasmocyte) | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-4 | 5.73e-3 |
| B cell (Plasmocyte) | Urate | Urate levels | ETC | Tin A | 2019 | NA | 288,649 | 1.00e-3 | 4.29e-2 |
| B cell (Plasmocyte) | Urate | Urate levels | ETC | Tin A | 2019 | NA | 288,649 | 1.00e-4 | 2.96e-2 |
| B cell (Plasmocyte) | Urate | Urate levels | ETC | Tin A | 2019 | NA | 288,649 | 1.00e-5 | 1.04e-2 |
| B cell (Plasmocyte) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-3 | 2.05e-2 |
| B cell (Plasmocyte) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-4 | 2.18e-2 |
| B cell (Plasmocyte) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-2 | 3.54e-2 |
| B cell (Plasmocyte) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-3 | 4.35e-2 |
| B cell (Plasmocyte) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 4.48e-2 |
| B cell (Plasmocyte) | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-4 | 1.20e-2 |
| B cell (Plasmocyte) | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-2 | 2.63e-2 |
| B cell (Plasmocyte) | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-3 | 3.21e-2 |
| B cell (Plasmocyte) | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-3 | 3.03e-2 |
| B cell (Plasmocyte) | Lung function | Lung function (FEV1) variance | ETC | Wang H | 2019 | NA | 317,285 | 5.00e-2 | 2.76e-2 |
| B cell (Plasmocyte) | Lung function | Lung function (FEV1) variance | ETC | Wang H | 2019 | NA | 317,285 | 1.00e-2 | 2.05e-2 |
| B cell (Plasmocyte) | Uterine fibroids and heavy menstrual bleeding | Uterine fibroids and heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 3,409 | 199,171 | 5.00e-2 | 8.69e-3 |
| B cell (Plasmocyte) | Uterine fibroids and heavy menstrual bleeding | Uterine fibroids and heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 3,409 | 199,171 | 1.00e-2 | 3.93e-2 |
| B cell (Plasmocyte) | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 5.00e-2 | 4.18e-2 |
| B cell (Plasmocyte) | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 5.00e-2 | 4.33e-2 |
| Epithelial cell (intermediated) | BMI by age | BMI at 6 months old | ETC | Helgeland O | 2019 | NA | 8,017 | 5.00e-2 | 4.34e-2 |
| B cell (Plasmocyte) | BMI by age | BMI at 8 months old | ETC | Helgeland O | 2019 | NA | 7,197 | 5.00e-2 | 3.54e-2 |
| Epithelial cell (intermediated) | BMI by age | BMI at 1.5 years old | ETC | Helgeland O | 2019 | NA | 6,800 | 1.00e-2 | 2.87e-2 |
| B cell (Plasmocyte) | BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 5.00e-2 | 5.13e-3 |
| B cell (Plasmocyte) | BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 1.00e-2 | 2.35e-3 |
| Epithelial cell (intermediated) | BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 1.42e-2 |
| Epithelial cell (intermediated) | BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 5.00e-2 | 2.63e-2 |
| Epithelial cell (intermediated) | BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 1.00e-2 | 3.38e-2 |
| B cell (Plasmocyte) | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-3 | 4.74e-2 |
| B cell (Plasmocyte) | Central corneal thickness | Central corneal thickness | ETC | Bonnemaijer PWM | 2019 | NA | 16,204 | 1.00e-3 | 9.12e-3 |
| B cell (Plasmocyte) | Central corneal thickness | Central corneal thickness | ETC | Bonnemaijer PWM | 2019 | NA | 16,204 | 1.00e-4 | 8.34e-3 |
| B cell (Plasmocyte) | IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.75e-2 |
| B cell (Plasmocyte) | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.17e-3 |
| B cell (Plasmocyte) | Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-2 | 1.83e-2 |
| B cell (Plasmocyte) | Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-3 | 2.28e-2 |
| B cell (Plasmocyte) | Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-4 | 1.61e-2 |
| B cell (Plasmocyte) | Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-5 | 2.20e-2 |
| B cell (Plasmocyte) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 5.00e-2 | 3.00e-2 |
| B cell (Plasmocyte) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-2 | 2.11e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.